Surface Pharmaceuticals

Surface Pharmaceuticals is a biopharmaceutical startup founded in 2017 that is dedicated to enhancing ocular health through advanced topical solutions for timely and effective dry eye disease recovery. The company's slogan encapsulates its mission to provide innovative ophthalmology solutions through the utilization of the propriety Klarity delivery system. This unique approach aims to safeguard and restore the ocular surface, catering to the needs of patients suffering from dry eye disease. Having recently secured a significant $5.76M Venture Round investment on 10 June 2021, Surface Pharmaceuticals demonstrates promising potential within the biopharma, health care, and pharmaceutical industries. Despite the lack of specific headquarters information, the startup's focus on leveraging advanced topical formulations signifies a commitment to driving advancements in ocular health. The recent investment signifies confidence from investors in the company's innovative approach to addressing dry eye disease. This funding injection is expected to further propel Surface Pharmaceuticals' efforts in developing effective and timely recovery solutions for patients. As the company continues to pioneer advancements in ocular health, its recent investment underscores the potential for growth and impact within the pharmaceutical and biopharmaceutical sectors.